Ras interference as cancer therapy

Activating point mutations of the small GTPase Ras are present in about 30% of all human tumors. Constitutively active Ras induces growth factor independent cell proliferation and cell survival. Oncogenic Ras appears to be essential for tumor progression and maintenance. Several therapeutic agents h...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cancer biology 2003-08, Vol.13 (4), p.267-273
Main Authors: Duursma, Anja M, Agami, Reuven
Format: Article
Language:English
Subjects:
Animals
Antisense
Biological and medical sciences
Cancer therapy
FTIs
Genes, ras
Genetic Therapy - methods
Humans
Medical sciences
Neoplasms - therapy
Ras
RNA Interference
RNAi
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Activating point mutations of the small GTPase Ras are present in about 30% of all human tumors. Constitutively active Ras induces growth factor independent cell proliferation and cell survival. Oncogenic Ras appears to be essential for tumor progression and maintenance. Several therapeutic agents have been developed to inhibit Ras, such as FTIs and antisense oligonucleotides. A new tool for blocking oncogenes in cancer cells has emerged with the discovery that RNA interference can specifically silence expression of endogenous human genes. The therapeutic potential of a RNAi-mediating vector was recently demonstrated by the stable suppression of oncogenic K-Ras in tumor cells.
ISSN:1044-579X
1096-3650
DOI:10.1016/S1044-579X(03)00040-3